SCHEMBL1625211

SCHEMBL1625211

CCc1nc2cc(Cl)ccc2n1-c1ccc(CCN(C(=O)O)S(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 1/20 0.44
CNR2 P34972 6/20 0.43
NTRK1 P04629 1/20 0.41
NTRK2 Q16620 1/20 0.41
PDE10A Q9Y233 1/20 0.40
HTT P42858 1/20 0.39
PPARG P37231 1/20 0.37
PPARD Q03181 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
CNR1 P21554 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PKM P14618 1/20 0.36
TBXA2R P21731 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1626185 0.93 PTGER4 (0.44) PTGER4CNR2NTRK1NTRK2PDE10A
SCHEMBL1624648 0.90 PTGER4 (0.45) PTGER4CNR2NTRK1NTRK2PDE10A
SCHEMBL1624296 0.89 PTGER4 (0.44) PTGER4CNR2NTRK1NTRK2PDE10A
SCHEMBL1626033 0.88 PTGER4 (0.45) PTGER4CNR2NTRK1NTRK2PDE10A
SCHEMBL1625541 0.88 PTGER4 (0.43) PTGER4CNR2NTRK1NTRK2PDE10A
SCHEMBL1624692 0.87 NTRK1 (0.55) PTGER4CNR2NTRK1NTRK2PDE10A
SCHEMBL1624322 0.87 PTGER4 (0.43) PTGER4CNR2NTRK1NTRK2PDE10A
SCHEMBL1626075 0.86 TP53 (0.44) PTGER4CNR2NTRK1NTRK2PDE10A
SCHEMBL1626179 0.86 PTGER4 (0.42) PTGER4CNR2NTRK1NTRK2PDE10A
SCHEMBL1625563 0.86 PTGER4 (0.44) PTGER4CNR2NTRK1NTRK2PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928119-B2 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PFIZER INC. (US) 2011-04-19 US disclosed
US-20070066618-A1 Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases PFIZER INC. 2007-03-22 US disclosed
US-7148234-B2 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PFIZER INC. (US) 2006-12-12 US disclosed
US-6710054-B2 CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS PFIZER INC 2004-03-23 US disclosed
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases SHIMOJO MASATO 2003-12-25 US disclosed
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2002-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, OPRM1 PTGER4 51/4885CNR2 133/4885NTRK1 3557/4885
US-20070066618-A1 Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases PTGER4, PTGER1, IL6 PTGER4 1/4885CNR2 165/4885NTRK1 2177/4885
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PTGER4, PTGER1, IL6 PTGER4 1/4885CNR2 165/4885NTRK1 2177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.